The fraction dose absorbed, in humans, and high jejunal human permeability relationship

Molecular Pharmaceutics

Volumn 9, Issue 6, 2012, Pages 1847-1851

  Dahan, Arik ^a   Lennernäs, Hans ^b   Amidon, Gordon L ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

biopharmaceutics classification system; fraction dose absorbed; intestinal permeability; oral absorption

Indexed keywords

ISOTRETINOIN; LOSARTAN; METOPROLOL; SOTALOL;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG DOSE; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; INTESTINE PRESSURE; IONIZATION; JEJUNUM; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

HUMANS; INTESTINAL ABSORPTION; ISOTRETINOIN; JEJUNUM; LOSARTAN; METOPROLOL; MODELS, BIOLOGICAL;

EID: 84862025527     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300140h     Document Type: Article

References (41)

1. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12 (3), 413-420.
2. CDER/FDA, Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release dosage forms based on a biopharmaceutical slassification system; Center for Drug Evaluation and Research: 2000.
3. Dahan, A.; Miller, J. M.; Amidon, G. L. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 2009, 11 (4), 740-746.
4. Lennernäs, H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007, 37 (10-11), 1015-51. (Pubitemid 350035536)
5. Lennernäs, H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J. Pharm. Pharmacol. 1997, 49 (7), 627-638. (Pubitemid 27341705)
6. Lennernäs, H. Human intestinal permeability. J. Pharm. Sci. 1998, 87 (4), 403-410. (Pubitemid 28175799)
7. Lennernäs, H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr. Drug Metab. 2007, 8 (7), 645-57. (Pubitemid 47578114)
8. Sun, D.; Lennernäs, H.; Welage, L. S.; Barnett, J. L.; Landowski, C. P.; Foster, D.; Fleisher, D.; Lee, K.-D.; Amidon, G. L. Comparison of human duodenum and caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 2002, 19 (10), 1400-1416. (Pubitemid 35266543)
9. Cook, J. A.; Davit, B. M.; Polli, J. E. Impact of biopharmaceutics classification system-based biowaivers. Mol. Pharmaceutics 2010, 7 (5), 1539-1544.
10. Roffey, S.; Obach, R.; Gedge, J.; Smith, D. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 2007, 39 (1), 17-43.
11. Dobson, P. D.; Kell, D. B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Discovery 2008, 7 (3), 205-220. (Pubitemid 351321232)
12. Sugano, K.; Kansy, M.; Artursson, P.; Avdeef, A.; Bendels, S.; Di, L.; Ecker, G. F.; Faller, B.; Fischer, H.; Gerebtzoff, G.; Lennernas, H.; Senner, F. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discovery 2010, 9 (8), 597-614.
13. Yu, L. X.; Amidon, G. L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 1999, 186 (2), 119.
14. Yu, L. X.; Lipka, E.; Crison, J. R.; Amidon, G. L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Delivery Rev. 1996, 19 (3), 359-376. (Pubitemid 26227526)
15. Tannergren, C.; Bergendal, A.; Lennernas, H.; Abrahamsson, B. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol. Pharmaceutics 2009, 6 (1), 60-73.
16. EMA, Guideline on the investigation of bioequivalence; European Medicines Agency: 2010.
17. Regardh, C.; Borg, K.; Johansson, R.; Johnsson, G.; Palmer, L. Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J. Pharmacokinet. Biopharm. 1974, 2 (4), 347-64.
18. Jobin, G.; Cortot, A.; Godbillon, J.; Duval, M.; Schoeller, J.; Hirtz, J.; Bernier, J. Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Br. J. Clin. Pharmacol. 1985, 19 (Suppl. 2), 97S-105S.
19. Masaoka, Y.; Tanaka, Y.; Kataoka, M.; Sakuma, S.; Yamashita, S. Site of drug absorption after oral administration: Assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur. J. Pharm. Sci. 2006, 29 (3-4), 240-250. (Pubitemid 44602413)
20. Chen, M.-L.; Yu, L. The use of drug metabolism for prediction of intestinal permeability. Mol. Pharmaceutics 2009, 6 (1), 74-81.
21. Yang, Y.; Faustino, P. J.; Volpe, D. A.; Ellison, C. D.; Lyon, R. C.; Yu, L. X. Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Mol. Pharmaceutics 2007, 4 (4), 608-614.
22. Dahan, A.; Miller, J. M.; Hilfinger, J. M.; Yamashita, S.; Yu, L. X.; Lennernäs, H.; Amidon, G. L. High-permeability criterion for BCS classification: Segmental/pH dependent permeability considerations. Mol. Pharmaceutics 2010, 7 (5), 1827-1834.
23. Amidon, K. S.; Langguth, P.; Lennernäs, H.; Yu, L.; Amidon, G. L. Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin. Pharmacol. Ther. 2011, 90 (3), 467-470.
24. Thiel-Demby, V. E.; Humphreys, J. E.; John Williams, L. A., St.; Ellens, H. M.; Shah, N.; Ayrton, A. D.; Polli, J. W. Biopharmaceutics classification system: Validation and learnings of an in vitro permeability assay. Mol. Pharmaceutics 2009, 6 (1), 11-18.
25. Dahan, A.; Amidon, G. L. Segmental dependent transport of low permeability compounds along the small intestine due to Pglycoprotein: The role of efflux transport in the oral absorption of BCS class III drugs. Mol. Pharmaceutics 2009, 6 (1), 19-28.
26. Dahan, A.; Sabit, H.; Amidon, G. L. Multiple efflux pumps are involved in the transepithelial transport of colchicine: Combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab. Dispos. 2009, 37 (10), 2028-2036.
27. Mouly, S.; Paine, M. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res. 2003, 20 (10), 1595-9. (Pubitemid 37268274)
28. Thorn, M.; Finnstrom, N.; Lundgren, S.; Rane, A.; Loof, L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol. 2005, 60 (1), 54-60. (Pubitemid 40942781)
29. Dahan, A.; West, B. T.; Amidon, G. L. Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur. J. Pharm. Sci. 2009, 36 (2-3), 320-329.
30. Sutcliffe, F.; Riley, S.; Kaser-Liard, B.; Turnberg, L.; Rowland, M. Absorption of drugs from human jejunum and ileum. Br. J. Clin. Pharmacol. 1988, 26, 206P-207P.
31. Dahan, A.; Amidon, G. L. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am. J. Physiol. 2009, 297 (2), G371-G377.
32. Giacomini, K.; Huang, S.; Tweedie, D.; Benet, L.; Brouwer, K.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K.; Hoffmaster, K.; Ishikawa, T.; Keppler, D.; Kim, R.; Lee, C.; Niemi, M.; Polli, J.; Sugiyama, Y.; Swaan, P.; Ware, J.; Wright, S.; Yee, S.; Zamek-Gliszczynski, M.; Zhang, L. Membrane transporters in drug development. Nat.Rev. Drug Discovery 2010, 9 (3), 215-236.
33. Cao, X.; Yu, L. X.; Barbaciru, C.; Landowski, C. P.; Shin, H.-C.; Gibbs, S.; Miller, H. A.; Amidon, G. L.; Sun, D. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol. Pharmaceutics 2005, 2 (4), 329-340. (Pubitemid 41186409)
34. Custodio, J. M.; Wu, C. Y.; Benet, L. Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Delivery Rev. 2008, 60 (6), 717.
35. Cao, X.; Gibbs, S.; Fang, L.; Miller, H.; Landowski, C.; Shin, H.; Lennernäs, H.; Zhong, Y.; Amidon, G.; Yu, L.; Sun, D. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 2006, 23 (8), 1675-86.
36. Chiou, W.; Barve, A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 1998, 15 (11), 1792-5. (Pubitemid 28524594)
37. Dahan, A.; Amidon, G. L. Grapefruit juice and its constituents augment colchicine intestinal absorption: Potential hazardous interaction and the role of P-glycoprotein. Pharm. Res. 2009, 26 (4), 883-892.
38. Kim, J. S.; Mitchell, S.; Kijek, P.; Tsume, Y.; Hilfinger, J.; Amidon, G. L. The suitability of an in situ perfusion model for permeability determinations: Utility for BCS class I biowaiver requests. Mol. Pharmaceutics 2006, 3 (6), 686-694. (Pubitemid 46087485)
39. Lennernäs, H. Animal data: the contributions of the Ussing chamber and perfusion systems to predicting human oral drug delivery in vivo. Adv. Drug Delivery Rev. 2007, 59 (11), 1103-1120. (Pubitemid 47615203)
40. Benet, L.; Amidon, G. L.; Barends, D.; Lennernäs, H.; Polli, J.; Shah, V.; Stavchansky, S.; Yu, L. The use of BDDCS in classifying the permeability of marketed drugs. Pharm. Res. 2008, 25 (3), 483-488.
41. Wu, C.-Y.; Benet, L. Z. Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 2005, 22 (1), 11-23. (Pubitemid 40558141)